Literature DB >> 17316167

Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain.

John K Wung1, George Perry, Aaron Kowalski, Peggy L R Harris, Glenda M Bishop, Mehul A Trivedi, Sterling C Johnson, Mark A Smith, David T Denhardt, Craig S Atwood.   

Abstract

Osteopontin (OPN) is a glycophosphoprotein expressed by several cell types and has pro-adhesive, chemotactic, and cytokine-like properties. OPN is involved in a number of physiologic and pathologic events including angiogenesis, apoptosis, inflammation, oxidative stress, remyelination, wound healing, bone remodeling, cell migration and tumorigenesis. Since these functions of OPN, and the events that it regulates, are involved with neurodegeneration, we examined whether OPN was differentially expressed in the hippocampus of the Alzheimer's disease (AD) compared with age-matched (59-93 years) control brain. We report for the first time the immunocytochemical localization of OPN in the cytoplasm of pyramidal neurons. In AD brains, there was a significant 41 % increase in the expression of neuron OPN compared with age-matched control brain. No staining of other neuronal cell types was observed. Additionally, there was a significant positive correlation between OPN staining intensity and both amyloid-beta load (r(2) = 0.25; P < 0.05; n = 20) and aging (r(2) = 0.32; P < 0.01; n = 20) among all control and AD subjects. Controlling for age indicated that OPN expression was significantly influenced by amyloid-beta load, but not age. While the functional consequences of this amyloid-beta associated increase in OPN expression are unclear, it is notable that OPN is primarily localized to those neurons that are known to be vulnerable to AD-related neurite loss, degeneration and death. Given that the induction of OPN expression (and amyloid-beta generation) is associated with remodeling and tumorigenesis, our results suggest that OPN may play a role in the aberrant re-entry of neurons into the cell cycle and/or neuronal remyelination in AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316167     DOI: 10.2174/156720507779939869

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  34 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury.

Authors:  Julie L Chan; Thomas M Reeves; Linda L Phillips
Journal:  Exp Neurol       Date:  2014-08-21       Impact factor: 5.330

3.  Acute intranasal osteopontin treatment in male rats following TBI increases the number of activated microglia but does not alter lesion characteristics.

Authors:  Amandine Jullienne; Mary Hamer; Elizabeth Haddad; Alexander Morita; Peter Gifford; Richard Hartman; William J Pearce; Jiping Tang; John H Zhang; Andre Obenaus
Journal:  J Neurosci Res       Date:  2019-03-20       Impact factor: 4.164

Review 4.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

5.  Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice.

Authors:  Walter Maetzler; Daniela Berg; Claudia Funke; Freya Sandmann; Holger Stünitz; Corina Maetzler; Cordula Nitsch
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

6.  Intranasal Delivery of RGD Motif-Containing Osteopontin Icosamer Confers Neuroprotection in the Postischemic Brain via αvβ3 Integrin Binding.

Authors:  Yin-Chuan Jin; Hahnbie Lee; Seung-Woo Kim; Il-Doo Kim; Hye-Kyung Lee; Yunjin Lee; Pyung-Lim Han; Ja-Kyeong Lee
Journal:  Mol Neurobiol       Date:  2015-10-19       Impact factor: 5.590

7.  Osteopontin is not critical for otoconia formation or balance function.

Authors:  Xing Zhao; Sherri M Jones; Wallace B Thoreson; Yunxia Wang Lundberg
Journal:  J Assoc Res Otolaryngol       Date:  2008-05-06

8.  The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems.

Authors:  Yasuto Kunii; Shin-ichi Niwa; Yoshiaki Hagiwara; Masahiro Maeda; Tsutomu Seitoh; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

9.  Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells.

Authors:  Dah-Yuu Lu; Wei-Lan Yeh; Ssu-Ming Huang; Chih-Hsin Tang; Hsiao-Yun Lin; Shao-Jiun Chou
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

10.  Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease.

Authors:  David J Bonda; Teresa A Evans; Corrado Santocanale; Jesús Catalá Llosá; Jose Viña; Vladan P Bajic; Rudy J Castellani; Sandra L Siedlak; George Perry; Mark A Smith; Hyoung-gon Lee
Journal:  Aging (Albany NY)       Date:  2009-04       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.